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DEAR EDITOR, A 5-year-old girl was referred to us for evaluation
of a pigmented birthmark, unchanged since birth, on her right
cheek. There was no other previous medical history of note
and no family history of relevant problems. Cutaneous exami-
nation revealed a pigmented keratinocytic epidermal naevus
following fine Blaschko lines on the right cheek and neck
(Fig. 1), and a solitary, 1-cm cafe-au-lait macule on the lower
leg. Subtle hemihypertrophy of the right cheek was noted,
including the tragus of the ear, which had appeared to pro-
gress over time. In conjunction, she was noted to have right-
sided hemihypertrophy of the tongue with intraoral pigmenta-
tion of the mucosal surfaces, linear naevoid-looking change
on the right side of the tongue and right-sided misalignment
of the teeth. Her parents also gave a history of frequent
malodorous right ear discharge. The patient was referred to
otorhinolaryngology, who diagnosed a severe right-sided con-
ductive hearing loss. The remainder of her physical examina-
tion was unremarkable. Magnetic resonance imaging
confirmed soft tissue hemihypertrophy of the cheek, with
extensive soft tissue overgrowth within the right external
auditory canal and middle-ear cleft, and a sclerotic bony spur
in the posterior inferior aspect of the external auditory canal
(Fig. 1g).
Mosaicism for a growth-promoting mutation was suspected.
With appropriate consent for genetic investigations a punch
skin biopsy was obtained from the epidermal naevus, and
DNA extracted directly by standard methods. DNA was also
extracted from a venous blood sample. Histology confirmed a
keratinocytic epidermal naevus (Fig. 2). Initial sequencing of
HRAS and KRAS hotspot mutations, as described in epidermal
naevus syndromes,1,2 was negative. However, Sanger sequenc-
ing for hotspot mutations in AKT1 revealed a heterozygous
missense mutation, c.49G>A, p.Glu17Lys, present in the epi-
dermal naevus but not the blood (Fig. 2). Although we only
have a single biopsy from this patient, given existing knowl-
edge of this particular mutation, postzygotic mosaicism is
highly likely to be the cause of her entire clinical phenotype
and not just the epidermal naevus.
In mosaic form, this is the characteristic causal mutation in
the first cohort of patients with clinically delineated Proteus
syndrome, as defined by strict diagnostic criteria.3,4 Proteus
syndrome is a rare overgrowth syndrome characterized by a
normal phenotype or limited features at birth followed by
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Fig 1. Increasing right-sided soft tissue growth over time. (a, b) Initial presentation and (c, d) months later. (e) Right-sided hypertrophy of the
tongue. (f) Epidermal naevus. (g) Axial T1-weighted image at the level of the nasopharynx showing asymmetry of the facial soft tissues,
mandible, parotid glands and tonsils, larger on the right side.
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progressive disproportionate, asymmetric overgrowth with
skeletal defects, dysregulated adipose tissue, pulmonary abnor-
malities, and a propensity to deep vein thrombosis and pul-
monary embolism. Patients may have dysmorphic facies,
intellectual disability and, in some cases, seizures and brain
malformations. Cutaneous lesions associated with Proteus syn-
drome include epidermal naevi, vascular malformations, lipo-
mas and the characteristic cerebriform connective tissue
naevus.
In 2001, Lindhurst et al. identified somatic activating muta-
tions in AKT1 as the cause of Proteus syndrome,3 discovering
the AKT1 mutation c.49G>A, p.Glu17Lys in the affected tissues
of 26 of 29 patients who met the clinical diagnostic criteria
for Proteus syndrome. Activating mutations of the AKT1 onco-
gene leads to Akt kinase activation, triggering the PI3K/Akt/
mammalian target of rapamycin pathway, a critical pathway in
the regulation of cellular proliferation and apoptosis. From
these published cases we can clearly see that a clinical diagno-
sis of Proteus syndrome is likely to be caused by AKT1 muta-
tion mosaicism in most, if not all, cases; however, it is now
also evident that the reverse is not necessarily true.
This case depicts the most restricted phenotype of AKT1
mosaicism, confirmed by sequencing, described so far, lim-
ited, presumably, by the timing of the postzygotic mutation
and the cell type affected. This mirrors the spectrum of sever-
ity seen in other known mosaic disorders involving oncogenes
and tumour suppressor genes, such as congenital melanocytic
naevus syndrome and the PIK3CA-related overgrowth spectrum
(PROS) disorders.5,6 Suspected cases of ‘mild’ Proteus syn-
drome have previously been described in the literature, prior
to the discovery of the underlying genetic mutation.7–10
Although, without molecular confirmation the description of
many of these cases may similarly represent milder pheno-
types of other segmental overgrowth syndromes, for example
the PIK3CA-related overgrowth spectrum. One previous case of
a limited Proteus phenotype, and corresponding AKT1 mosaic
genotype, has been described in a 33-year-old man presenting
in childhood with bilateral plantar cerebriform collageno-
mas.11 Similar to our case, this case does not meet the estab-
lished clinical diagnostic criteria for Proteus syndrome;
however, the presence of the characteristic cerebriform col-
lagenomas could alert clinicians to the possibility of more
restricted AKT1 mosaicism. Our case extends this spectrum into
the much milder phenotype of epidermal naevus with under-
lying overgrowth. Clinicians should be alerted to this
restricted phenotype and consider AKT1 screening in undiag-
nosed cases of mild overgrowth in association with correlating
cutaneous lesions, and also as part of genetic investigations for
epidermal naevi.
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